Guselkumab for the treatment of palmoplantar pustulosis

References

• de Waal AC, van de Kerkhof PC. Pustulosis palmoplantaris is a disease distinct from psoriasis. J Dermatolog Treat. 2011;22:102–105.
   PubMed Web of Science ®Google Scholar
• Becher G, Jamieson L, Leman J. Palmoplantar pustulosis–a retrospective review of comorbid conditions. J Eur Acad Dermatol Venereol. 2015;29:1854–1856.
   PubMed Web of Science ®Google Scholar
• Umezawa Y, Nakagawa H, Tamaki K. Phase III clinical study of maxacalcitol ointment in patients with palmoplantar pustulosis: A randomized, double-blind, placebo-controlled trial. J Dermatol. 2016;43:288–293.
   PubMed Web of Science ®Google Scholar
• Su LN, Ren J, Cheng SM, et al. UVA1 vs. narrowband UVB phototherapy in the treatment of palmoplantar pustulosis: a pilot randomized controlled study. Lasers Med Sci. 2017;32:1819–1823.
   PubMed Web of Science ®Google Scholar
• Fumimori T, Tsuruta D, Kawakami T, et al. Effect of monochromatic excimer light on palmoplantar pustulosis: a clinical study performed in a private clinic by a dermatological specialist. J Dermatol. 2013;40:1004–1007.
   PubMed Web of Science ®Google Scholar
• Barber H, Eyre J. Acrodermatitis continua (hallopeau) vel dermatitis repens (crocker). Br J Dermatol. 1927;39:485–520.
   Google Scholar
• Navarini AA, Burden AD, Capon F, et al. European consensus statement on phenotypes of pustular psoriasis. J Eur Acad Dermatol Venereol. 2017;31:1792–1799.
   PubMed Web of Science ®Google Scholar
• Ingram JT. Pustular psoriasis. AMA Arch Derm. 1958;77:314–318.
   PubMedGoogle Scholar
• Andrews GC, Birkman FW, Kelly HJ. Recalcitrant pustular eruptions of the palms and soles. Arch Dermatol Syphilol. 1934;29:548–563.
   Google Scholar
• Andrews GC, Machacek GF. Pustular bacterids of the hands and feet. Arch Dermatol Syphilol. 1935;32:837–847.
   Google Scholar
• Everall J. Intractable pustular eruptions of the hands and feet; a review of 70 patients. Br J Dermatol. 1957;69:269–272.
   PubMed Web of Science ®Google Scholar
• Thomsen K. Pustulosis palmaris et plantaris treated with methotrexate. Acta Derm Venereol. 1971;51:397–400.
   PubMed Web of Science ®Google Scholar
• Hellgren L, Mobacken H. Pustulosis palmaris et plantaris. Prevalence, clinical observations and prognosis. Acta Derm Venereol. 1971;51:284–288.
   PubMed Web of Science ®Google Scholar
• Lever W. Histopathology of the Skin. 3rd ed. Philadelphia: Lippincott; 1961. p. 127.
   Google Scholar
• Misiak-Galazka M, Wolska H, Rudnicka L. What do we know about palmoplantar pustulosis? J Eur Acad Dermatol Venereol. 2017;31:38–44.
   PubMed Web of Science ®Google Scholar
• Marrakchi S, Guigue P, Renshaw BR, et al. Interleukin-36-receptor antagonist deficiency and generalized pustular psoriasis. N Engl J Med. 2011;365:620–628.
   PubMed Web of Science ®Google Scholar
• Onoufriadis A, Simpson MA, Pink AE, et al. Mutations in IL36RN/IL1F5 are associated with the severe episodic inflammatory skin disease known as generalized pustular psoriasis. Am J Hum Genet. 2011;89:432–437.
   PubMed Web of Science ®Google Scholar
• Setta-Kaffetzi N, Navarini AA, Patel VM, et al. Rare pathogenic variants in IL36RN underlie a spectrum of psoriasis-associated pustular phenotypes. J Invest Dermatol. 2013;133:1366–1369.
   PubMed Web of Science ®Google Scholar
• Takahashi T, Fujimoto N, Kabuto M, et al. Mutation analysis of IL36RN gene in Japanese patients with palmoplantar pustulosis. J Dermatol. 2017;44:80–83.
   PubMed Web of Science ®Google Scholar
• Mossner R, Frambach Y, Wilsmann-Theis D, et al. Palmoplantar pustular psoriasis is associated with missense variants in CARD14, but not with loss-of-function mutations in IL36RN in European Patients. J Invest Dermatol. 2015;135:2538–2541.
   PubMed Web of Science ®Google Scholar
• Tobita R, Egusa C, Maeda T, et al. A novel CARD14 variant, homozygous c.526G>C (p.Asp176His), in an adolescent Japanese patient with palmoplantar pustulosis. Clin Exp Dermatol. 2019;44:694–696.
   PubMed Web of Science ®Google Scholar
• Murakami M, Ohtake T, Horibe Y, et al. Acrosyringium is the main site of the vesicle/pustule formation in palmoplantar pustulosis. J Invest Dermatol. 2010;130:2010–2016.
   PubMed Web of Science ®Google Scholar
• Eriksson MO, Hagforsen E, Lundin IP, et al. Palmoplantar pustulosis: a clinical and immunohistological study. Br J Dermatol. 1998;138:390–398.
   PubMed Web of Science ®Google Scholar
• Uehara M, Ofuji S. The morphogenesis of pustulosis palmaris et plantaris. Arch Dermatol. 1974;109:518–520.
   PubMedGoogle Scholar
• Masuda-Kuroki K, Murakami M, Kishibe M, et al. Diagnostic histopathological features distinguishing palmoplantar pustulosis from pompholyx. J Dermatol. 2019;46:399–408.
   PubMed Web of Science ®Google Scholar
• Murakami M, Kaneko T, Nakatsuji T, et al. Vesicular LL-37 contributes to inflammation of the lesional skin of palmoplantar pustulosis. PLoS One. 2014;9:e110677.
   PubMed Web of Science ®Google Scholar
• Murakami M, Kameda K, Tsumoto H, et al. TLN-58, an Additional hCAP18 processing form, found in the lesion vesicle of palmoplantar pustulosis in the skin. J Invest Dermatol. 2017;137:322–331.
   PubMed Web of Science ®Google Scholar
• Murakami M, Hagforsen E, Morhenn V, et al. Patients with palmoplantar pustulosis have increased IL-17 and IL-22 levels both in the lesion and serum. Exp Dermatol. 2011;20:845–847.
   PubMed Web of Science ®Google Scholar
• Ozawa M, Terui T, Tagami H. Localization of IL-8 and complement components in lesional skin of psoriasis vulgaris and pustulosis palmaris et plantaris. Dermatology. 2005;211:249–255.
   PubMed Web of Science ®Google Scholar
• Skov L, Beurskens FJ, Zachariae CO, et al. IL-8 as antibody therapeutic target in inflammatory diseases: reduction of clinical activity in palmoplantar pustulosis. J Immunol. 2008;181:669–679.
   PubMed Web of Science ®Google Scholar
• Johnston A, Xing X, Wolterink L, et al. IL-1 and IL-36 are dominant cytokines in generalized pustular psoriasis. J Allergy Clin Immunol. 2017;140:109–120.
   PubMed Web of Science ®Google Scholar
• Li N, Yamasaki K, Saito R, et al. Alarmin function of cathelicidin antimicrobial peptide LL37 through IL-36gamma induction in human epidermal keratinocytes. J Immunol. 2014;193:5140–5148.
   PubMed Web of Science ®Google Scholar
• Henry CM, Sullivan GP, Clancy DM, et al. Neutrophil-derived proteases escalate inflammation through activation of IL-36 family cytokines. Cell Rep. 2016;14:708–722.
   PubMed Web of Science ®Google Scholar
• Vigne S, Palmer G, Lamacchia C, et al. IL-36R ligands are potent regulators of dendritic and T cells. Blood. 2011;118:5813–5823.
   PubMed Web of Science ®Google Scholar
• Xiaoling Y, Chao W, Wenming W, et al. Interleukin (IL)-8 and IL-36gamma but not IL-36Ra are related to acrosyringia in pustule formation associated with palmoplantar pustulosis. Clin Exp Dermatol. 2019;44:52–57.
   PubMed Web of Science ®Google Scholar
• Piskin G, Sylva-Steenland RM, Bos JD, et al. In vitro and in situ expression of IL-23 by keratinocytes in healthy skin and psoriasis lesions: enhanced expression in psoriatic skin. J Immunol. 2006;176:1908–1915.
   PubMed Web of Science ®Google Scholar
• Terui T, Kobayashi S, Okubo Y, et al. Efficacy and safety of guselkumab, an anti-interleukin 23 monoclonal antibody, for palmoplantar pustulosis: a randomized clinical trial. JAMA Dermatol. 2018;154:309–316.
   PubMed Web of Science ®Google Scholar
• Terui T, Kobayashi S, Okubo Y, et al. Efficacy and safety of guselkumab in Japanese patients with palmoplantar pustulosis: a phase 3 randomized clinical trial. JAMA Dermatol. 2019. DOI:10.1001/jamadermatol.2019.1394.
   PubMed Web of Science ®Google Scholar
• Yawalkar N, Hunger RE. Successful treatment of recalcitrant palmoplantar pustular psoriasis with sequential use of infliximab and adalimumab. Dermatology. 2009;218:79–83.
   PubMed Web of Science ®Google Scholar
• Aljuhani F, Tournadre A, Tatar Z, et al. The SAPHO syndrome: a single-center study of 41 adult patients. J Rheumatol. 2015;42:329–334.
   PubMed Web of Science ®Google Scholar
• Olazagasti JM, Ma JE, Wetter DA. Clinical features, etiologic factors, associated disorders, and treatment of palmoplantar pustulosis: the mayo clinic experience, 1996-2013. Mayo Clin Proc. 2017;92:1351–1358.
   PubMed Web of Science ®Google Scholar
• Bissonnette R, Poulin Y, Bolduc C, et al. Etanercept in the treatment of palmoplantar pustulosis. J Drugs Dermatol. 2008;7:940–946.
   PubMedGoogle Scholar
• Lopez-Estebaranz JL, Ruiz-Genao D. Pustular psoriasis, palmoplantar psoriasis, erythodermal psoriasis and etanercept. Actas Dermosifiliogr. 2010;101(Suppl 1):35–39.
   PubMedGoogle Scholar
• Kasche A, Pfab F, Hein R, et al. Severe psoriasis pustulosa palmaris et plantaris (Barber-Konigsbeck) treated successfully with soluble tumour necrosis factor receptor fusion protein (etanercept). J Eur Acad Dermatol Venereol. 2007;21:255–257.
   PubMed Web of Science ®Google Scholar
• Abourazzak FE, Hachimi H, Kadi N, et al. Etanercept in the treatment of SAPHO syndrome: which place? Eur J Rheumatol. 2014;1:125–128.
   PubMedGoogle Scholar
• Barland C, Kerdel FA. Addition of low-dose methotrexate to infliximab in the treatment of a patient with severe, recalcitrant pustular psoriasis. Arch Dermatol. 2003;139:949–950.
   PubMedGoogle Scholar
• Fairhurst DA, Sheehan-Dare R. Autoimmune hepatitis associated with infliximab in a patient with palmoplantar pustular psoriaisis. Clin Exp Dermatol. 2009;34:421–422.
   PubMed Web of Science ®Google Scholar
• Burgemeister LT, Baeten DL, Tas SW. Biologics for rare inflammatory diseases: TNF blockade in the SA PHO syndrome. Neth J Med. 2012;70:444–449.
   PubMed Web of Science ®Google Scholar
• Bissonnette R, Nigen S, Langley RG, et al. Increased expression of IL-17A and limited involvement of IL-23 in patients with palmo-plantar (PP) pustular psoriasis or PP pustulosis; results from a randomised controlled trial. J Eur Acad Dermatol Venereol. 2014;28:1298–1305.
   PubMed Web of Science ®Google Scholar
• Pinto-Almeida T, Torres T, Sanches M, et al. Treatment of palmoplantar pustulosis with ustekinumab–the importance of interfering with the IL23/Th17 pathway. Eur J Dermatol. 2013;23:916–917.
   PubMed Web of Science ®Google Scholar
• Bertelsen T, Kragballe K, Johansen C, et al. Efficacy of ustekinumab in palmoplantar pustulosis and palmoplantar pustular psoriasis. Int J Dermatol. 2014;53:e464–6.
   PubMed Web of Science ®Google Scholar
• Torre KM, Payette MJ. Combination biologic therapy for the treatment of severe palmoplantar pustulosis. JAAD Case Rep. 2017;3:240–242.
   PubMedGoogle Scholar
• Kromer C, Wilsmann-Theis D, Gerdes S, et al. Drug survival and reasons for drug discontinuation in palmoplantar pustulosis: a retrospective multicenter study. J Dtsch Dermatol Ges. 2019;17:503–516.
   Web of Science ®Google Scholar
• Mrowietz U, Bachelez H, Burden AD, et al. Secukinumab for moderate-to-severe palmoplantar pustular psoriasis: results of the 2PRECISE study. J Am Acad Dermatol. 2019;80:1344–1352.
   PubMed Web of Science ®Google Scholar
• Pinter A, Wilsmann-Theis D, Peitsch WK et al. Interleukin-17 receptor A blockade with brodalumab in palmoplantar pustular psoriasis: report on four cases. J Dermatol 2019;46:426–430.
   PubMed Web of Science ®Google Scholar
• Nakao M, Asano Y, Kamata M, et al. Successful treatment of palmoplantar pustular psoriasis with brodalumab. Eur J Dermatol. 2018;28:538–539.
   PubMed Web of Science ®Google Scholar
• Bachelez H, Choon SE, Marrakchi S, et al. Inhibition of the interleukin-36 pathway for the treatment of generalized pustular psoriasis. N Engl J Med. 2019;380:981–983.
   PubMed Web of Science ®Google Scholar
• Gerdes S, Franke J, Domm S, et al. Ustekinumab in the treatment of palmoplantar pustulosis. Br J Dermatol. 2010;163:1116–1118.
   PubMed Web of Science ®Google Scholar
• de Unamuno-bustos B, Ballester-Sanchez R, Oliver-Martinez V, et al. Ustekinumab for the treatment of palmar-plantar pustulosis. Actas Dermosifiliogr. 2011;102:833–835.
   PubMedGoogle Scholar
• Carrascosa de Lome R, Conde ME, de la Cueva Dobao P. Refractory palmoplantar pustulosis succesfully treated with apremilast. Dermatol Ther. 2020;33:e13230.
   PubMed Web of Science ®Google Scholar
• Eto A, Nakao M, Furue M. Three cases of palmoplantar pustulosis successfully treated with apremilast. J Dermatol. 2019;46:e29–e30.
   PubMed Web of Science ®Google Scholar
• Haebich G, Kalavala M. Successful treatment of refractory palmoplantar pustulosis with apremilast. Clin Exp Dermatol. 2017;42:471–473.
   PubMed Web of Science ®Google Scholar